ALK+ Metastatic Non-Small Cell Lung Cancer: The Importance of Biomarker Testing

This trial will assess an individualized neoantigen therapy plus Keytruda in some patients with non-small cell lung cancer.

February brought in multiple FDA approvals in the oncology space. Here’s an overview of some of the most recent ones.

The risk of cardiovascular disease is elevated in cancer survivors, regardless of treatment, and is influenced by cancer type and treatment-related factors.

Last week, we saw a few moving parts in the regulatory space, from new NCCN guidelines for pediatric neuroblastoma treatment to FDA Fast Tracks and Priority Reviews

Aspirin did not impact CVD incidence; however, risk may be higher in those with metastatic, hematological and lung cancer and following chemotherapy.

Two patients reflected on how extraordinary their oncology nurses are — even noting that they forget about their cancer when talking with their nurses.